SML1949

Synta66

≥98% (HPLC)

• Sinónimos: 4-Pyridinecarboxamide, N-(2′,5′-dimethoxy[1,1′-biphenyl]-4-yl)-3-fluoro-, GSK1349571A, N-(2′,5′-Dimethoxy[1,1′-biphenyl]-4-yl)-3-fluoro-4-pyridinecarboxamide, S66, Synta 66, Synta-66
• Fórmula empírica (notación de Hill): C₂₀H₁₇FN₂O₃
• Número CAS: 835904-51-3
• Peso molecular: 352.36
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 20 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: O=C(NC1=CC=C(C2=C(OC)C=CC(OC)=C2)C=C1)C3=CC=NC=C3F
• InChI key: GFEIWXNLDKUWIK-UHFFFAOYSA-N

Descripción

Application

Synta66 has been used:

• as a Ca²⁺ release-activated calcium (CRAC) channel inhibitor to study its effects on ORAI isoforms
• as an ORAI1 blocker to study its effects on the entry of Ca²⁺ in chronic lymphocytic leukemia (CLL) B cells
• as a CRAC blocker to study its effects on the influx of Ca²⁺ by store-operated Ca²⁺ entry (SOCE) in enamel cells

Biochem/physiol Actions

A selective SOCE inhibitor that blocks CRAC current (ICRAC) without significant off-target potency or affinity.

Synta66 (S66) is a CRAC (Ca2+ release-activated Ca2+) channel inhibitor that blocks SOCE (store-operated Ca2+ entry) upon Ca2+ depletion from intracellular stores by thapsigargin in human vascular smooth muscle cells (VSMCs) with high potency (IC50 = 26 nM & 43 nM based on maximum Ca2+ level & rate of increase, respectly). Synta66 exhibits no affinity toward a range of receptors and ion channels (e.g. L-type Ca2+ channel) and does not affect TRPC1/5-mediated SOCE or store-operated non-selective cationic current. Leukocytes are reported to be less sensitive to CRAC inhibition by Synta66 (IC50 = 1.76 μM/HL-60, 1 ?M/Jurkat, 1.4 μM/rat RBL).

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable